Gapping down
In reaction to disappointing earnings/guidance:
In reaction to disappointing earnings/guidance:
- GNE -14.7%, VRA -14.2%, EXPR -11.9%,
- ALQA -11.5%, (also initiated a process of identifying strategic alternatives for the contract manufacturing business )
- ARA -10.9%, HYGS -8.9%, PQ -8.7%, URBN -6.7%, BOJA -6.1%, CIEN -3.9%, BOBE -3.6%
- RGNX -2.6%, (also announces that the first patient in a Phase I/II clinical trial of REGENXBIO's investigational gene therapy RGX-501 for the treatment of homozygous familial hypercholesterolemia has been dosed)
- KODK -2.5%, RRR -1.4%
Select metals/mining stocks trading lower:
- GFI -3.5%, SBGL -3.4%, AG -2.6%, HMY -2.3%, BHP -1.9%, AUY -0.8%, ABX -0.7%
Select oil/gas related names showing early weakness:
- RIG -1.4%, RDS.A -1.2%, MRO -1%, BP -0.8%, TOT -0.8%
Other news:
- HIIQ -15% (launches a secondary underwritten public offering of shares of its Class A common stock )
- GEO -6.3% (prices its previously announced public offering of 6,000,000 shares at $41.75/share)
- LADR -4.8% (prices 3 mln common stock offering by selling stockholders for gross proceeds of approx. $42 mln)
- FOXF -4.2% (announces secondary offering of 5,108,718 shares by one of its existing stockholders)
- LAND -3.9% (to sell approx. 1.4 mln shares of its common stock in an underwritten public offering)
- CAT -2.1% (NY Times report discussing allegations of tax fraud)
- COTV -2% (prices offering of 8.42 mln shares of common stock, by certain stockholders at a $36.00 per share)
- NVO -1.2% (Bloomberg details that Novo Nordisk (NVO) might miss its diabetics treatment targets)
Analyst comments:
- GOLD -2.1% (downgraded to Underperform at RBC Capital Mkts)
- BT -1.4% (downgraded to Neutral from Buy at Goldman)